相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- KRAS, the most frequently mutated oncogene across cancers, was long considered undruggable due to its smooth surface and high-affinity GTP-binding site. - The G12C mutation's cysteine residue enables covalent inhibition, leading to the approval of sotorasib (2021) and adagrasib (2022) in the US. - In CodeBreaK 200, sotorasib improved progression-free survival versus docetaxel (5.6 vs. 4.5 months, HR 0.66) in previously treated KRAS G12C NSCLC. - In colorectal cancer, KRAS G12C inhibition alone shows limited efficacy, requiring combination with anti-EGFR antibodies such as cetuximab or panitumumab.
- RedHill Biopharma's RHB-204 demonstrated comparable MAP killing efficacy to RHB-104 in vitro testing, achieving similar antimicrobial activity with lower doses of two active ingredients. - The next-generation formulation offers potential for reduced toxicity and side effects while maintaining the therapeutic approach that showed 64% improvement over standard care in Phase 3 trials. - RHB-204's planned Phase 2 study will be the first clinical trial in a specifically defined MAP-positive Crohn's disease patient population, representing a potentially paradigm-changing treatment approach. - The Crohn's disease market is projected to grow from $13.6 billion in 2024 to over $19 billion by 2033, presenting significant commercial opportunity for novel therapies.
- TAHO Pharmaceuticals has submitted a New Drug Application to the FDA for TAH3311, the world's first apixaban oral dissolving film designed for patients with swallowing difficulties. - The innovative formulation addresses a critical unmet need for stroke survivors, as over 50% experience dysphagia and face heightened risks of pneumonia and malnutrition. - TAH3311 utilizes TAHO's proprietary Transepithelial Delivery System platform to eliminate the need for swallowing solid dosage forms, reducing choking and aspiration pneumonia risks. - The submission represents a significant regulatory milestone toward U.S. market entry for this patient-centered anticoagulant therapy solution.
- The phase 3b ProvIDHe study demonstrated that ivosidenib achieved a median progression-free survival of 4.7 months and overall survival of 15.5 months in patients with IDH1-mutated cholangiocarcinoma. - Real-world data from 262 patients across 80 sites in 15 countries confirmed the efficacy profile established in the pivotal ClarIDHy trial that led to FDA approval. - The study enrolled heavily pretreated patients with a median of 2 prior lines of therapy, showing a disease control rate of 51.5% and objective response rate of 5.7%.
- Hillstar Bio appointed Maude Tessier, Ph.D., as Chief Operating Officer and Shiva Krupa, Ph.D., MBA, as Vice President of Program Management to strengthen leadership capabilities. - The strategic hires support advancement of the company's lead TRBV9 program for axial spondyloarthritis treatment toward clinical entry in 2026. - Tessier brings 18 years of biopharmaceutical experience including successful financing and partnership leadership, while Krupa contributes extensive R&D program management expertise. - The company recently secured $67 million in Series A financing and focuses on precision immunology approaches that selectively target pathogenic immune cells while sparing healthy ones.
- Tubulis announced that the first antibody-drug conjugate from its strategic partnership with Bristol Myers Squibb has entered clinical development, marking a significant milestone in their 2023 collaboration agreement. - The ADC candidate leverages Tubulis' proprietary Tubutecan technology, which combines their P5 conjugation system with an exatecan payload to create stable, targeted cancer therapeutics with minimized systemic toxicity. - This represents the third Tubutecan-based ADC to reach clinical trials within 12 months, following Tubulis' wholly owned programs TUB-030 and TUB-040, demonstrating the platform's versatility for treating solid tumors.
- BlueSphere Bio has appointed Alan Korman, Ph.D., a veteran immunotherapy researcher with over 30 years of experience, as Chief Scientific Officer to advance its T cell-based therapy pipeline. - Dr. Korman, who has served on BlueSphere's board since 2020, previously led groundbreaking immune checkpoint inhibitor research at Bristol-Myers Squibb and Medarex, directing the preclinical development of Yervoy and Opdivo. - The appointment strengthens BlueSphere's clinical programs, which include BSB-1001 for leukemias and the upcoming TCX-102 program targeting mutant NPM-1 in AML, with an IND expected in Q2 2025.
- Bristol-Myers Squibb's Opdualag, the first FDA-approved LAG-3 inhibitor combination, generated $58 million in second-quarter sales following its March approval for metastatic melanoma. - Clinical data shows Opdualag more than doubles progression-free survival compared to PD-1 monotherapy, positioning it as a potential new standard of care with anticipated EU approval in coming weeks. - BMS expects Opdualag to reach $4 billion in peak sales across multiple cancer indications, strengthening its immuno-oncology portfolio as competitors including Merck develop rival LAG-3 inhibitors.
• Bristol-Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) combination has received FDA approval for first-line treatment of unresectable or metastatic hepatocellular carcinoma, demonstrating a 21% reduced risk of death compared to standard therapies. • The CheckMate-9DW trial showed significant survival benefits with a median overall survival of 23.7 months for the immunotherapy combination versus 20.6 months for tyrosine kinase inhibitors, potentially establishing a new standard of care. • This approval marks a significant advancement for HCC patients, addressing an unmet need in a disease whose incidence has tripled over four decades, though treatment decisions may be influenced by the combination's known toxicity profile.
- Interim analysis of ENLIGHTEN trial reveals ozanimod treatment reduced mean GFAP concentration from 115.0 to 103.2 pg/mL over one year in relapsing multiple sclerosis patients. - GFAP levels showed significant correlations with various MRI parameters, including positive associations with lesion volumes and negative correlations with brain volume measures. - Patients demonstrated cognitive improvements with ozanimod treatment, with 48.1% achieving clinically meaningful improvement in SDMT scores after one year.
